Bladder Cancer | Tumor

FDA's Jelmyto Approval Offers Patients 'Very Sorely Needed' Treatment Option

April 22nd 2020, 10:00pm


The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.

Padcev and Keytruda Combination Shows Promise for More Urothelial Carcinoma Options

April 17th 2020, 12:13am


Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.

FDA Approves First Low-Grade Upper Tract Urothelial Cancer Therapy

April 15th 2020, 11:32pm


The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.

Looking Toward Combination Therapies in Metastatic Bladder Cancer

April 14th 2020, 1:00am


Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.

Immunotherapy After Chemotherapy Improves Outcomes in Metastatic Bladder Cancer

April 10th 2020, 1:00am


Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.

Electronic Cigarette Use and Risk of Bladder Cancer

April 2nd 2020, 7:00pm


A new study links e-cigarette use to bladder cancer but experts say more research is needed.

Experts Call for Refined Treatment Paradigm in Urothelial Cancer

March 17th 2020, 1:37am


There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.

The Future of Immunotherapy in Bladder Cancer

February 23rd 2020, 12:00am


Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.

Padcev, Keytruda Combination Proves Impactful for Patients with Metastatic Urothelial Cancer

February 20th 2020, 12:00am


The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.

Padcev Combination Shows Promise in Patients with Metastatic Bladder Cancer

February 16th 2020, 12:00am


The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.